University of Hertfordshire

  • G. Bersani
  • F. S. Bersani
  • E. Caroti
  • P. Russo
  • G. Albano
  • G. Valeriani
  • C. Imperatori
  • A. Minichino
  • G. Manuali
  • O. Corazza
View graph of relations
Original languageEnglish
Number of pages6
Pages (from-to)547-552
JournalEuropean Review for Medical and Pharmacological Sciences
Journal publication date2016
Volume20
Issue3
Publication statusPublished - 2016

Abstract

OBJECTIVE: Cannabis use is frequent among depressed patients and may lead to the so-called "amotivational syndrome", which combines symptoms of affective flattening and loss of emotional reactivity (i.e. the socalled "negative" symptomatology). The aim of this study was to investigate the negative symptomatology in depressed patients with concomitant cannabis use disorders (CUDs) in comparison with depressed patients without CUDs. PATIENTS AND METHODS: Fifty-one patients with a diagnosis of Major Depressive Disorder (MDD) and concomitant CUD and fiftyone MDD patients were enrolled in the study. The 21-Item Hamilton Depression Rating Scale (HDRS) and the negative symptoms subscales of the Positive and Negative Syndrome Scale (PANSS) were used to assess depressive and negative symptomatology. RESULTS: Patients with cannabis use disorders presented significantly more severe negative symptoms in comparison with patients without cannabis use (15.18 ± 2.25 vs 13.75 ± 2.44; t100 = 3.25 p = 0.002). DISCUSSION: A deeper knowledge of the "negative" psychopathological profile of MDD patients who use cannabis may lead to novel etiopathogenetic models of MDD and to more appropriate treatment approaches.

ID: 13220759